Search
Atopic Dermatitis Paid Clinical Trials in Alabama
A listing of 16 Atopic Dermatitis clinical trials in Alabama actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 16 of 16
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Atopic Dermatitis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Alabama currently has 16 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Birmingham, Mobile, Huntsville and Anniston.
Featured Trial
Eczema Clinical Trial for Children & Adolsecents
Recruiting
Enrolling candidates diagnosed with Atopic Dermatitis (Eczema). Compensation available.
Conditions:
Atopic Dermatitis
Eczema
Atopic Dermatitis Eczema
Dermatitis
Atopic
Featured Trial
Eczema Clinical Study
Recruiting
The purpose of this clinical study is to see whether an oral investigational medication can help to treat symptoms of moderate to severe Atopic Dermatitis (eczema).
Conditions:
Eczema
Atopic Dermatitis Eczema
Atopic Eczema
Eczema
Atopic
* Compensation for time may be available
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Recruiting
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/20/2024
Locations: Cahaba Dermatology & Skin Health Center, Birmingham, Alabama
Conditions: Atopic Dermatitis
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Recruiting
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama
Conditions: Atopic Dermatitis
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Recruiting
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/29/2024
Locations: Allervie Clinical Research, Birmingham, Alabama
Conditions: Atopic Dermatitis
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Birmingham, Alabama
Conditions: Atopic Dermatitis
13 - 16 of 16